<DOC>
	<DOCNO>NCT00186342</DOCNO>
	<brief_summary>The purpose study determine tolerability efficacy treat patient age 51-60 acute leukemia treat myelodysplastic syndrome ( MDS ) myeloproliferative disorder ( MPD ) .</brief_summary>
	<brief_title>Sibling Unrelated Donor Hematopoietic Cell Transplant Hematologic Malignancies</brief_title>
	<detailed_description>To learn whether new preparative regimen prepare patient bone marrow transplantation useful patient 50 year age whether useful patient myelodysplastic syndrome .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<criteria>1 ) Patients age 5160 acute nonlymphocytic leukemia first subsequent remission acute lymphocytic leukemia first remission high risk feature include elevated white blood cell count presentation , cytogenetic abnormality , extramedullary leukemia , ALL great first remission patient chronic myelogenous leukemia stage histocompatible sibling donor . 2 ) Patients myelodysplastic syndrome include patient refractory anemia excess blast refractory anemia excess blast transformation . 3 ) Patients myeloproliferative disorder give poor longterm diseasefree survival , myeloid metaplasia myeloid fibrosis . 4 ) Patients secondary myelodysplasia follow cytotoxic chemotherapy . Organ dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>51 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>